Clinical, Pathological, and Genetic Characteristics of Patients with Digenic Alport Syndrome

Yuta Inoki, MD [1], Tomoko Horinouchi, MD, PhD [1,*], Tomohiko Yamamura MD, PhD [1], Shingo Ishimori MD, PhD [1], Yuta Ichikawa MD [1], Yu Tanaka MD [1], Chika Ueda MD [1], Hideaki Kitakado MD [1], Atsushi Kondo MD, PhD [1], Nana Sakakibara MD, PhD [1], China Nagano MD, PhD [1], Kandai Nozu MD, PhD [1]

[1] Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan

***Corresponding author**

Tomoko Horinouchi, MD, PhD

Department of Pediatrics, Kobe University Graduate School of Medicine

7-5-1 Kusunoki-cho, Chuo, Kobe, Hyogo 650-0017, Japan

E-mail: tohori@med.kobe-u.ac.jp

Tel: +81-78-382-5111

Supplemental Table 1. List of 68 podocyte-related genes included in targeted sequencing analysis within a clinically approved gene panel test developed in our laboratory.

ACTN4	*COQ2*	*ITSN1*	*MAGI2*	*PAX2*	*TPRKB*
ADCK4	*COQ6*	*ITSN2*	*MYH9*	*PDSS2*	*TRIM8*
ANKFY1	*CRB2*	*KANK1*	*MYO1E*	*PLCE1*	*TRPC6*
ANLN	*CUBN*	*KANK2*	*NPHS1*	*PODXL*	*TTC21B*
ARHGAP24	*DLC1*	*KANK4*	*NPHS2*	*PRDM15*	*WDR4*
ARHGDIA	*EMP2*	*KIRREL1*	*NUP85*	*PTPRO*	*WDR73*
AVIL	*FAT1*	*LAGE3*	*NUP93*	*SCARB2*	*WT1*
CD2AP	*GAPVD1*	*LAMA5*	*NUP107*	*SGPL1*	*XPO5*
CKD20	*GON7*	*LAMB2*	*NUP133*	*SMARCAL1*	
COL4A3	*INF2*	*LMNA*	*NUP160*	*TNS2*	
COL4A4	*ITGA3*	*LMX1B*	*NUP205*	*TBC1D8B*	
COL4A5	*ITGB4*	*MAFB*	*OSGEP*	*TP53RK*	

Supplemental Figure 1



Figure S1. Probability of developing ESKD in Alport syndrome cases with digenic *COL4A3* and *COL4A4* variants including previously reported[1] cases compared with that in autosomal dominant Alport syndrome (ADAS) cases in our cohort ($P = 0.011$).

1. Savige J, Renieri A, Ars E, et al. Digenic Alport syndrome. *Clin J Am Soc Nephrol*. 2022;17(11):1697-1706. https://doi.org/10.2215/CJN.03120322